Agilent Technologies Inc. (NYSE: A) has extended its diagnostics franchise into a critical oncology niche. On July 23, European regulators certified the company’s PD-L1 IHC 22C3 pharmDx test (Code SK006) as a companion diagnostic for epithelial ovarian, fallopian tube, and primary peritoneal carcinoma. The approval enables pathologists to identify patients who may benefit from Merck’s blockbuster immunotherapy Keytruda (pembrolizumab). While the indication is narrow, it marks the eighth CE-marked label for the 22C3 assay in the EU, reinforcing a compounding strategy that contrasts with rivals chasing single blockbuster products.
Bull Case: A High-Margin Diagnostics Machine Compounding Indications
Each new label leverages an assay already installed in pathology labs worldwide, requiring minimal incremental R&D spend. This high-margin revenue model was underscored just nine days prior when the FDA approved a related PD-L1 test (28-8 pharmDx) for esophageal and gastric cancers. Agilent has also grown inorganically, closing its acquisition of Biocare Medical in June to deepen its clinical pathology footprint—the exact segment where the ovarian cancer approval resides. Together, the regulatory cadence and M&A strategy signal a company methodically expanding its diagnostics moat one indication at a time.
Bear Case: Crowded Field and a Stumbling Giant Next Door
Companion diagnostics is not Agilent’s alone to win. Danaher Corporation (NYSE: DHR), through its Leica Biosystems unit, competes directly for the same pathology lab budgets. On July 14, Danaher agreed to acquire StatLab Medical Products to bolster its histology and AI-pathology pipeline. Yet Danaher’s own shares cratered 14% on July 21 after it trimmed core revenue growth guidance, despite beating earnings and raising its profit forecast. The selloff is a stark reminder that life-sciences tools names can be punished severely for modest guidance cuts. If sector sentiment sours, Agilent’s premium multiple—trading at roughly 20.6× forward earnings as of August 2—may offer little downside protection.
Valuation Convergence: Market Pricing Similar Risk Profiles
Hedge fund interest has cooled on both names. Agilent’s hedge fund holders fell to 63 from 71 in the prior quarter, while Danaher’s dropped to 110 from 125. Short interest remains modest at ~2.7% of Agilent’s float versus ~1.6% for Danaher, indicating neither stock faces heavy organized skepticism. Notably, the forward P/E gap has narrowed sharply: Danaher now trades at ~22.9× forward earnings, not far above Agilent’s 20.6×. The convergence suggests the market assigns comparable risk-adjusted valuations despite differing catalysts—Agilent’s steady label expansions versus Danaher’s broader portfolio exposure and recent guidance reset.
Small Approvals, Bigger Execution Questions
The EU ovarian cancer nod may not be financially material in isolation, but it reinforces a strategy of compounding small label expansions rather than swinging for a single home run. The real question is whether that steady cadence translates into meaningful revenue growth and operational execution, especially as a larger rival like Danaher navigates its own pathology lab challenges. Investors should monitor testing volume adoption rates for Keytruda in the new indication and any further M&A or guidance updates from both companies.
FAQ
- What is a companion diagnostic and why does it matter for Agilent? A companion diagnostic is a test that identifies patients most likely to benefit from a specific therapy. For Agilent, each new companion diagnostic label extends the utility of its existing PD-L1 assay platform, driving recurring reagent and instrument revenue without requiring new product development.
- How does Danaher’s Leica Biosystems compete with Agilent in this space? Leica Biosystems offers competing immunohistochemistry (IHC) assays and pathology workflow solutions. Danaher’s recent acquisition of StatLab Medical Products aims to strengthen its histology and AI-driven pathology pipeline, directly targeting the same lab budgets Agilent pursues.
- Why did Danaher’s stock drop 14% despite beating earnings? Danaher lowered its core revenue growth outlook, signaling potential demand softness in its life sciences and diagnostics segments. In high-multiple tool companies, guidance reductions often trigger disproportionate selloffs because valuations embed near-perfect execution assumptions.
